RT Journal Article
SR Electronic
T1 c-kit Expression in Dedifferentiated and Well-differentiated Liposarcomas; Immunohistochemistry and Genetic Analysis
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 2215
OP 2220
VO 25
IS 3B
A1 SHALINI TAYAL
A1 ELIZABETH CLASSEN
A1 LYNNE BEMIS
A1 WILLIAM A. ROBINSON
YR 2005
UL http://ar.iiarjournals.org/content/25/3B/2215.abstract
AB Background: c-kit expression by immunohistochemistry has been utilized to identify cancer patients who can be treated with imatinib-mesylate. In gastrointestinal stromal tumors (GISTs), an activating mutation in c-kit predicts treatment response; its presence in other soft tissue tumors is unexplored. Materials and Methods: We evaluated seven cases of dedifferentiated liposarcomas (DDLS) and compared those with seven well-differentiated liposarcomas (WDLS). Immunohistochemical staining for c-kit was performed using a polyclonal antibody. Using PCR, exons 9, 10-11, 12-13 and 17 of c-kit were amplified and direct DNA sequencing performed. Results: Two out of 7 (30%) DDLS showed focal weak immunoreactivity with c-kit; no (0%) WDLS stained with c-kit. Seven out of 7 (100%) DDLS showed an allelic variation in exon 10, with a single base pair substitution (A>C) at codon 541; 3/7 (43%) WDLS showed the same change. Conclusion: c-kit immunoreactivity did not correlate with the change in DNA sequence; DDLS showed a consistent allelic variation in c-kit that may have significant prognostic, diagnostic and therapeutic implications. Copyright© 2005 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved